Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • enfortumab vedotin
Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study
Posted inClinical Updates Wellness & Lifestyle

Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study

Posted by By MedXY 08/03/2025
The EV-302 trial shows enfortumab vedotin plus pembrolizumab improves survival and quality of life over platinum-based chemotherapy in untreated advanced urothelial cancer patients.
Read More
  • Sudden Cardiac Death: Early Signs, Risk Factors, and Prevention
  • 20 Practical Habits to Prevent Cancer in Daily Life
  • Understanding Early Puberty in Children: Causes, Risks, and Prevention
  • Bé gái 6 tuổi được chẩn đoán dậy thì sớm! Bác sĩ cảnh báo về các “thực phẩm bổ dưỡng” và “dụng cụ ăn uống”
  • Protect Your Knees for Longevity: Avoid These Harmful Movements
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer cardiovascular health clinical trial clinical trials diabetes diagnosis diet epidemiology exercise FDA FDA approval health healthcare HIV Hypertension immunotherapy longevity maternal health men's health Menopause mental health multiple myeloma nutrition obesity PCOS Pediatrics phase 3 trial Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep targeted therapy treatment type 2 diabetes Vaccine weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top